Global and India Pleuromutilin Antibiotic Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and India Pleuromutilin Antibiotic Market Report & Forecast 2024-2034
Pleuromutilin is a broad-spectrum diterpene antibiotic produced by Pleurotus mutilus. It is the precursor of semi-synthetic derivatives of pleuromutilin and can effectively inhibit most Gram-negative bacteria. positive bacteria and some Gram-negative bacteria.
The global Pleuromutilin Antibiotic revenue was US$ 97.3 million in 2022 and is forecast to a readjusted size of US$ 115.7 million by 2029 with a CAGR of 5.0% during the forecast period (2024-2034).
In India, the Pleuromutilin Antibiotic revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
Pleuromutilin’s market is driven by its effectiveness against specific bacterial infections and its widespread use in the veterinary and poultry medicine sectors. Its successful application in veterinary medicine and increasing demand have propelled market growth. Additionally, concerns about antibiotic resistance have prompted the livestock industry to adopt more sustainable veterinary medicines, with Pleuromutilin being considered a relatively low-resistance option, further boosting market demand. However, the Pleuromutilin market also faces several challenges. One of these challenges is the continuous rise in antibiotic resistance, which may limit its long-term effectiveness. Furthermore, some regions and markets may have stricter regulations on antibiotic use, posing challenges to market access for Pleuromutilin. Additionally, the veterinary sector’s interest in alternative treatment methods and greener veterinary medicines could impact the growth of the Pleuromutilin market. Therefore, the market needs to continually address challenges such as antibiotic resistance and regulatory restrictions to maintain sustainable growth.
This report focuses on global and India Pleuromutilin Antibiotic market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Pleuromutilin Antibiotic will continue to grow rapidly in the future.
Global Pleuromutilin Antibiotic Scope and Market Size
Pleuromutilin Antibiotic market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Pleuromutilin Antibiotic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the Pleuromutilin Antibiotic market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
Sunny Biotech
Hebei Weiyuan
Shandong Shengli
Shandong Lukang
Qingdao Dierman
Qilu Pharma
Huvepharma
Novartis
Vethellas
Elanco
Segment by Type
Premix
API Powder
Livestock
Poultry
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Pleuromutilin Antibiotic definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Pleuromutilin Antibiotic companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Pleuromutilin Antibiotic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pleuromutilin Antibiotic sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
The global Pleuromutilin Antibiotic revenue was US$ 97.3 million in 2022 and is forecast to a readjusted size of US$ 115.7 million by 2029 with a CAGR of 5.0% during the forecast period (2024-2034).
In India, the Pleuromutilin Antibiotic revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
Pleuromutilin’s market is driven by its effectiveness against specific bacterial infections and its widespread use in the veterinary and poultry medicine sectors. Its successful application in veterinary medicine and increasing demand have propelled market growth. Additionally, concerns about antibiotic resistance have prompted the livestock industry to adopt more sustainable veterinary medicines, with Pleuromutilin being considered a relatively low-resistance option, further boosting market demand. However, the Pleuromutilin market also faces several challenges. One of these challenges is the continuous rise in antibiotic resistance, which may limit its long-term effectiveness. Furthermore, some regions and markets may have stricter regulations on antibiotic use, posing challenges to market access for Pleuromutilin. Additionally, the veterinary sector’s interest in alternative treatment methods and greener veterinary medicines could impact the growth of the Pleuromutilin market. Therefore, the market needs to continually address challenges such as antibiotic resistance and regulatory restrictions to maintain sustainable growth.
This report focuses on global and India Pleuromutilin Antibiotic market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Pleuromutilin Antibiotic will continue to grow rapidly in the future.
Global Pleuromutilin Antibiotic Scope and Market Size
Pleuromutilin Antibiotic market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Pleuromutilin Antibiotic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the Pleuromutilin Antibiotic market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
By Company
Sunny Biotech
Hebei Weiyuan
Shandong Shengli
Shandong Lukang
Qingdao Dierman
Qilu Pharma
Huvepharma
Novartis
Vethellas
Elanco
Segment by Type
Premix
API Powder
Segment by Application
Livestock
Poultry
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Pleuromutilin Antibiotic definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Pleuromutilin Antibiotic companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Pleuromutilin Antibiotic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pleuromutilin Antibiotic sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices